|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.270 USD | +1.76% |
|
+2.09% | +3.43% |
| 06-29 | Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index | CI |
| 06-29 | Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer | CI |
Evolution of the Average Target: Xilio Therapeutics, Inc.
Evolution of the Target Price: Xilio Therapeutics, Inc.
Changes in Analyst Recommendations: Xilio Therapeutics, Inc.
de.gXnyqo_nUhP9tFij58FDMEtqvya5cc2Rmn_3cKV2cOI.sDC87dquOUfM8gnAhbIldD0I2mvwOYGk2RKfJ9QARYPUTarrxJIFX6z6DQ~a9af5390f4de8f8de7e09c370f6629f4
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +115.75% | |||
| +20.14% | |||||
| +8.01% | |||||
| +18.39% | |||||
| +30.18% | |||||
| +35.75% | |||||
| -0.54% | |||||
| +23.26% | |||||
| +3.79% | |||||
| +15.13% | |||||
| Average | +26.99% | |||||
| Weighted average by Cap. | +19.04% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.270USD
Average target price
20.00USD
Spread / Average Target
+115.75%
High Price Target
20.00USD
Spread / Highest target
+115.75%
Low Price Target
20.00USD
Spread / Lowest Target
+115.75%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Leerink Partners | |
| Morgan Stanley | |
| Chardan Research | |
| Raymond James | |
| HC Wainwright | |
| Cowen | |
| Guggenheim |
SellBuy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.270USD
Average target price
20.00USD
Spread / Average Target
+115.75%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- XLO Stock
- Consensus Xilio Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
